Ondine Biomedical Inc. NPV (CDI) (OBI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

6.60p
   
  • Change Today:
      1.48p
  • 52 Week High: 19.00
  • 52 Week Low: 4.50
  • Currency: UK Pounds
  • Shares Issued: 226.75m
  • Volume: 1,172,667
  • Market Cap: £14.97m

Ondine announces expanded Canadian availability of Steriwave

By Josh White

Date: Friday 13 Oct 2023

LONDON (ShareCast) - (Sharecast News) - Life sciences company Ondine Biomedical announced the expansion of the availability of its Steriwave nasal photo disinfection technology on Friday across various hospitals in Canada.
The AIM-traded firm said the technology aimed to curb the prevalence of healthcare-associated infections (HAIs) and tackle the growing crisis of antimicrobial resistance (AMR).

It said the latest establishment to take up the solution was the Queen Elizabeth II Health Sciences Centre in Halifax - Nova Scotia's largest hospital and a facility affiliated with Dalhousie University.

The board said the situation with HAIs in Canada was alarmingly significant, with one in nine patients in Canadian hospitals acquiring an HAI, annually leading to around 12,000 deaths.

At the same time, the problem of HAIs was being exacerbated by increasing instances of AMR, rendering some widely used antibiotics futile.

As a result, one in every 19 deaths in Canada could be attributed to antibiotic-resistant infections.

In economic terms, the financial burden of AMR on the Canadian healthcare sector was projected to swell substantially, from $1.4bn to an estimated $7.6bn per annum by 2050.

"It is hugely satisfying that Steriwave is now available in hospitals from coast to coast across Canada, giving patients enhanced protection against post-surgical infections," said chief executive officer Carolyn Cross.

"This new hospital deployment demonstrates Steriwave's growing status as an effective alternative to topical antibiotics for infection prevention that easily fits into existing hospital workflows.

"In the US we are continuing to move forward with our phase three trial in partnership with HCA Healthcare who are providing invaluable input and support."

At 1116 BST, shares in Ondine Biomedical were up 10.21% at 7.99p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OBI Market Data

Currency UK Pounds
Share Price 6.60p
Change Today 1.48p
% Change 28.78 %
52 Week High 19.00
52 Week Low 4.50
Volume 1,172,667
Shares Issued 226.75m
Market Cap £14.97m

OBI Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
47.6% below the market average47.6% below the market average47.6% below the market average47.6% below the market average47.6% below the market average
72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average
Price Trend
89.75% below the market average89.75% below the market average89.75% below the market average89.75% below the market average89.75% below the market average
63.64% below the sector average63.64% below the sector average63.64% below the sector average63.64% below the sector average63.64% below the sector average
Income Not Available
Growth
45.42% below the market average45.42% below the market average45.42% below the market average45.42% below the market average45.42% below the market average
60% below the sector average60% below the sector average60% below the sector average60% below the sector average60% below the sector average

OBI Dividends

No dividends found

Trades for 03-May-2024

Time Volume / Share Price
16:45 27,427 @ 6.60p
16:45 2,571 @ 6.60p
16:45 19,285 @ 6.60p
16:45 1,822 @ 6.60p
16:45 749 @ 6.60p

OBI Key Personnel

Chair Jean Charest
CEO Carolyn Cross

Top of Page